预测受试者的进化IvE认知衰退到阿尔茨海默病 通过机器学习:PREVIEW研究协议
Salvatore Mazzeo1,2, Michael Lassi3, Sonia Padiglioni2,4
1Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, Florence, 50134, Italy.
BMC neurology
|August 12, 2023
概括
这项研究使用机器学习来识别主观认知衰退 (SCD) 个体的早期阿尔茨海默病 (AD). 目标是开发具有成本效益的非侵入性工具,用于早期AD检测和治疗.
科学领域:
- 神经学 神经学
- 生物技术是生物技术.
- 数据科学数据科学数据科学
背景情况:
- 主观认知衰退 (SCD) 可能代表阿尔茨海默病 (AD) 的早期症状阶段.
- 随着疾病修饰疗法 (DMT) 的出现,准确识别早期的AD至关重要.
- 需要具有成本效益的,非侵入性的工具来检测那些正在发展为AD痴呆症的SCD患者.
研究的目的:
- 描述PREVIEW前性队列研究的协议.
- 识别可访问,非侵入性评估的特征,以检测高风险发展为AD痴呆症的SCD患者.
- 开发一种机器学习算法,用于预测SCD患者的AD风险.
主要方法:
- 招募被诊断患有SCD的患者.
- 进行全面的评估,包括临床,神经心理,遗传 (APOE,BDNF) 和电生理学评估.
- 进行腰部穿刺以测量AD生物标志物 (Aβ42,t-tau,p-tau) 并使用机器学习分析数据.
主要成果:
- 该研究将使用收集的数据来训练机器学习算法.
- 该算法将旨在确定SCD患者AD和痴呆症进展的风险.
- 预期的结果将为AD风险估计提供具有成本效益和可扩展的工具提供证据.
结论:
- 这项研究开创了机器学习用于预测SCD患者的AD.
- 这些发现可能会导致开发全球可扩展的,具有成本效益的工具,用于早期发现AD.
- 早期识别有风险的个体对于及时干预新出现的DMT至关重要.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
01:30Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139